SLK

Summary

SLK (STE20 like kinase, HGNC:11088) is a protein-coding gene on chromosome 10q24.33-q25.1, encoding STE20-like serine/threonine-protein kinase (Q9H2G2). Mediates apoptosis and actin stress fiber dissolution.

Enables protein homodimerization activity and protein serine/threonine kinase activity. Involved in several processes, including cytoplasmic microtubule organization; protein autophosphorylation; and regulation of focal adhesion assembly. Located in perinuclear region of cytoplasm.

Source: NCBI Gene 9748 — RefSeq curated summary.

At a glance

• GWAS associations: 10
• Clinical variants (ClinVar): 157 total — 1 likely-pathogenic
• Druggable target: yes — 81 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_014720

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:11088
Approved symbol	SLK
Name	STE20 like kinase
Location	10q24.33-q25.1
Locus type	gene with protein product
Status	Approved
Aliases	STK2, se20-9, KIAA0204
Ensembl gene	ENSG00000065613
Ensembl biotype	protein_coding
OMIM	616563
Entrez	9748

Gene structure

Transcript identifiers

Ensembl transcripts: 15 — 14 protein_coding, 1 protein_coding_CDS_not_defined

ENST00000335753, ENST00000369755, ENST00000474260, ENST00000672560, ENST00000932919, ENST00000932920, ENST00000932921, ENST00000946372, ENST00000946373, ENST00000946374, ENST00000946375, ENST00000946376, ENST00000946377, ENST00000946378, ENST00000946379

RefSeq mRNA: 2 — MANE Select: NM_014720 NM_001304743, NM_014720

CCDS: CCDS7553, CCDS76334

Canonical transcript exons

ENST00000369755 — 19 exons

Exon	Start	End
ENSE00000515224	103992598	103992646
ENSE00000515225	103992984	103993133
ENSE00000515231	104005561	104005691
ENSE00000515232	104005912	104006035
ENSE00000723471	103998899	103998971
ENSE00000723472	103999119	103999313
ENSE00000723473	103999867	103999948
ENSE00000723474	104001444	104001572
ENSE00000723475	104002172	104003527
ENSE00000723483	104019734	104019922
ENSE00000987678	104010816	104010908
ENSE00001271668	104021620	104021733
ENSE00001271679	104020488	104020613
ENSE00001271692	104018784	104018908
ENSE00001271701	104008177	104008356
ENSE00001271743	103990675	103990839
ENSE00001450811	104025574	104029233
ENSE00003464481	104018160	104018289
ENSE00003842727	103967140	103967895

Expression profiles

Bgee: expression breadth ubiquitous, 293 present calls, max score 98.82.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 13.3619 / max 431.3695, expressed in 1785 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
106844	13.3619	1785

Top tissues by expression

295 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
esophagus squamous epithelium	UBERON:0006920	98.82	gold quality
endothelial cell	CL:0000115	98.67	gold quality
amniotic fluid	UBERON:0000173	98.33	gold quality
renal glomerulus	UBERON:0000074	98.29	gold quality
metanephric glomerulus	UBERON:0004736	98.14	gold quality
tongue squamous epithelium	UBERON:0006919	97.95	gold quality
squamous epithelium	UBERON:0006914	97.68	gold quality
calcaneal tendon	UBERON:0003701	97.60	gold quality
choroid plexus epithelium	UBERON:0003911	97.60	gold quality
Brodmann (1909) area 23	UBERON:0013554	97.40	gold quality
oral cavity	UBERON:0000167	97.36	gold quality
gingival epithelium	UBERON:0001949	97.13	gold quality
gingiva	UBERON:0001828	97.00	gold quality
epithelium of esophagus	UBERON:0001976	96.86	gold quality
pharyngeal mucosa	UBERON:0000355	96.84	gold quality
epithelium of nasopharynx	UBERON:0001951	96.07	gold quality
germinal epithelium of ovary	UBERON:0001304	96.04	gold quality
parietal pleura	UBERON:0002400	95.94	gold quality
penis	UBERON:0000989	95.89	gold quality
middle temporal gyrus	UBERON:0002771	95.80	gold quality
urethra	UBERON:0000057	95.63	gold quality
pleura	UBERON:0000977	95.48	gold quality
saphenous vein	UBERON:0007318	95.33	gold quality
mucosa of paranasal sinus	UBERON:0005030	95.27	gold quality
palpebral conjunctiva	UBERON:0001812	95.19	gold quality
visceral pleura	UBERON:0002401	95.19	gold quality
sural nerve	UBERON:0015488	94.71	gold quality
lower esophagus mucosa	UBERON:0035834	94.71	gold quality
skin of hip	UBERON:0001554	94.69	gold quality
synovial joint	UBERON:0002217	94.61	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-GEOD-130148	yes	4.29
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

177 targeting SLK, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-3924	100.00	72.09	2394
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-188-3P	100.00	68.76	1240
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-200B-3P	100.00	73.31	2693
HSA-MIR-200C-3P	100.00	73.35	2685
HSA-MIR-429	100.00	73.44	2698
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-6833-3P	100.00	70.63	3197
HSA-MIR-4768-5P	100.00	69.49	2861
HSA-MIR-186-5P	99.99	70.83	3707
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-4500	99.99	72.72	2367
HSA-MIR-1184	99.99	68.19	1458
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-4803	99.98	71.99	3117
HSA-MIR-4482-3P	99.98	72.50	3147
HSA-MIR-548N	99.98	71.94	4170
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-548AN	99.97	70.91	2817
HSA-MIR-3658	99.96	73.87	4379
HSA-MIR-548AA	99.96	70.64	3753
HSA-MIR-548AP-3P	99.96	70.64	3753
HSA-MIR-548T-3P	99.96	70.64	3753
HSA-MIR-493-5P	99.96	72.47	2382
HSA-MIR-9-3P	99.96	70.88	2068

Literature-anchored findings (GeneRIF, showing 10)

• v-Src-dependent down-regulation of the Ste20-like kinase SLK through casein kinase II. (PMID:16837460)
• we show that a novel isoform of SPS1-related proline alanine-rich kinase (SPAK/STE20) is involved in this inflammatory signaling cascade (PMID:17321610)
• Protein kinase LOSK is required for radial microtubule organization and for the proper localization of Golgi complex in various cell types. (PMID:18287541)
• Studies define an interaction between Neu and SLK signaling in the regulation of cancer cell motility. (PMID:19525980)
• It was shown that lymphocyte-oriented and STE20 kinase were sufficient to restrict ezrin function to the apical domain. Both kinases were enriched in microvilli and locally activated there. (PMID:23209304)
• The fact that SLK (LOSK) phosphorylates only a minor isoform 1A of p150(Glued) suggests that transport and microtubule-organizing functions of dynactin are distinctly divided between the two isoforms (PMID:23985322)
• SLK activated ERMs, together with Galphai, are critical for the correct localization of LGN-NuMA force generator complexes and hence for proper spindle orientation. (PMID:24958772)
• SLK interacts with Tpr and alpha-actinin-4 in cells, and these protein-protein interactions may control the subcellular localization and the biological activity of SLK. (PMID:26094769)
• The inhibition of SLK by RNA interference significantly suppressed the invasion ability of glioma, and on protein level, knock- down of SLK leaded to an up-regulation of E-cadherin and a down-regulation of Vimentin in glioma cells. (PMID:29534578)
• SLK-mediated actin cytoskeletal reorganization may facilitate force transmission between the contractile units and the extracellular matrix. (PMID:31913659)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	slkb	ENSDARG00000012574
danio_rerio	slka	ENSDARG00000061525
mus_musculus	Slk	ENSMUSG00000025060
rattus_norvegicus	Slk	ENSRNOG00000011339

Paralogs (35): MAP3K14 (ENSG00000006062), MAP4K3 (ENSG00000011566), MAP4K5 (ENSG00000012983), MAP2K3 (ENSG00000034152), MAP4K4 (ENSG00000071054), STK10 (ENSG00000072786), PAK3 (ENSG00000077264), STRADB (ENSG00000082146), MAP3K1 (ENSG00000095015), STK4 (ENSG00000101109), PAK5 (ENSG00000101349), STK24 (ENSG00000102572), STK3 (ENSG00000104375), MAP4K1 (ENSG00000104814), MAP3K8 (ENSG00000107968), MAP2K6 (ENSG00000108984), NEK4 (ENSG00000114904), STK25 (ENSG00000115694), NRK (ENSG00000123572), PAK4 (ENSG00000130669), STK26 (ENSG00000134602), TAOK3 (ENSG00000135090), PAK6 (ENSG00000137843), MINK1 (ENSG00000141503), PAK1 (ENSG00000149269), TAOK2 (ENSG00000149930), TNIK (ENSG00000154310), TAOK1 (ENSG00000160551), MAP4K2 (ENSG00000168067), OXSR1 (ENSG00000172939), MAP3K19 (ENSG00000176601), PAK2 (ENSG00000180370), SBK2 (ENSG00000187550), STK39 (ENSG00000198648), STRADA (ENSG00000266173)

Protein

Protein identifiers

STE20-like serine/threonine-protein kinase — Q9H2G2 (reviewed: Q9H2G2)

Alternative names: CTCL tumor antigen se20-9, STE20-related serine/threonine-protein kinase, Serine/threonine-protein kinase 2

All UniProt accessions (2): Q9H2G2, A0A5F9ZH68

UniProt curated annotations — full annotation on UniProt →

Function. Mediates apoptosis and actin stress fiber dissolution.

Subcellular location. Cytoplasm.

Tissue specificity. Ubiquitously expressed. Highest expression is found in heart and in skeletal muscle.

Post-translational modifications. Proteolytically cleaved by caspase-3. Autophosphorylated.

Similarity. Belongs to the protein kinase superfamily. STE Ser/Thr protein kinase family. STE20 subfamily.

Isoforms (2)

UniProt ID	Names	Canonical?
Q9H2G2-1	1	yes
Q9H2G2-2	2

RefSeq proteins (2): NP_001291672, NP_055535* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000719	Prot_kinase_dom	Domain
IPR001943	UVR_dom	Domain
IPR008271	Ser/Thr_kinase_AS	Active_site
IPR011009	Kinase-like_dom_sf	Homologous_superfamily
IPR017441	Protein_kinase_ATP_BS	Binding_site
IPR022165	PKK	Family
IPR051585	STE20_Ser/Thr_Kinases	Family

Pfam: PF00069, PF12474

Catalyzed reactions (Rhea), 2 shown:

• L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + H(+) (RHEA:17989)
• L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + ADP + H(+) (RHEA:46608)

UniProt features (82 total): modified residue 23, helix 16, sequence variant 9, strand 8, compositionally biased region 6, region of interest 5, turn 3, domain 2, binding site 2, coiled-coil region 2, chain 1, active site 1, site 1, splice variant 1, mutagenesis site 1, sequence conflict 1

Structure

Experimental structures (PDB)

7 structures.

PDB	Method	Resolution (Å)
6HVD	X-RAY DIFFRACTION	1.63
4USF	X-RAY DIFFRACTION	1.75
2J51	X-RAY DIFFRACTION	2.1
2JFL	X-RAY DIFFRACTION	2.2
2UV2	X-RAY DIFFRACTION	2.3
8BEM	X-RAY DIFFRACTION	2.6
2JFM	X-RAY DIFFRACTION	2.85

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9H2G2-F1	65.67	0.32

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (2): 155 (proton acceptor); 438–439 (cleavage; by caspase-3)

Ligand- & substrate-binding residues (2): 40–48; 63

Post-translational modifications (23): 14, 183, 189, 330, 340, 341, 344, 347, 348, 354, 372, 518, 565, 569, 571, 647, 655, 667, 777, 779 …

Mutagenesis-validated functional residues (1):

Position	Phenotype
63	loss of activity.

Function

Pathways and Gene Ontology

Reactome pathways

7 pathways

ID	Pathway
R-HSA-8980692	RHOA GTPase cycle
R-HSA-9013026	RHOB GTPase cycle
R-HSA-9013106	RHOC GTPase cycle
R-HSA-162582	Signal Transduction
R-HSA-194315	Signaling by Rho GTPases
R-HSA-9012999	RHO GTPase cycle
R-HSA-9716542	Signaling by Rho GTPases, Miro GTPases and RHOBTB3

MSigDB gene sets: 246 (showing top): GOBP_CYTOPLASMIC_MICROTUBULE_ORGANIZATION, GOBP_FOCAL_ADHESION_ASSEMBLY, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, IVANOVA_HEMATOPOIESIS_MATURE_CELL, MITSIADES_RESPONSE_TO_APLIDIN_DN, GOBP_REGULATION_OF_CELL_JUNCTION_ASSEMBLY, GOBP_REGULATION_OF_CELLULAR_COMPONENT_BIOGENESIS, SHIPP_DLBCL_CURED_VS_FATAL_DN, EFC_Q6, RODWELL_AGING_KIDNEY_NO_BLOOD_DN, GOBP_CELL_JUNCTION_ORGANIZATION, BLALOCK_ALZHEIMERS_DISEASE_UP, DACOSTA_UV_RESPONSE_VIA_ERCC3_COMMON_DN, TGACATY_UNKNOWN, ATGCTGG_MIR338

GO Biological Process (8): apoptotic process (GO:0006915), regulation of cell migration (GO:0030334), cytoplasmic microtubule organization (GO:0031122), intracellular signal transduction (GO:0035556), regulation of apoptotic process (GO:0042981), protein autophosphorylation (GO:0046777), regulation of focal adhesion assembly (GO:0051893), protein phosphorylation (GO:0006468)

GO Molecular Function (11): protein serine/threonine kinase activity (GO:0004674), ATP binding (GO:0005524), identical protein binding (GO:0042802), protein homodimerization activity (GO:0042803), cadherin binding (GO:0045296), protein serine kinase activity (GO:0106310), nucleotide binding (GO:0000166), protein kinase activity (GO:0004672), protein binding (GO:0005515), kinase activity (GO:0016301), transferase activity (GO:0016740)

GO Cellular Component (5): cytoplasm (GO:0005737), cytosol (GO:0005829), cell leading edge (GO:0031252), perinuclear region of cytoplasm (GO:0048471), extracellular exosome (GO:0070062)

Reactome top-level categories

Rollup of top-4 pathways:

Category	Pathways
RHO GTPase cycle	3
Signaling by Rho GTPases, Miro GTPases and RHOBTB3	1
Signaling by Rho GTPases	1
Signal Transduction	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	4
intracellular anatomical structure	2
protein kinase activity	2
cytoplasm	2
programmed cell death	1
apoptotic signaling pathway	1
execution phase of apoptosis	1
cell migration	1
regulation of cell motility	1
microtubule cytoskeleton organization	1
supramolecular fiber organization	1
signal transduction	1
apoptotic process	1
regulation of programmed cell death	1
protein phosphorylation	1
regulation of cell-matrix adhesion	1
focal adhesion assembly	1
regulation of cell-substrate junction assembly	1
phosphorylation	1
protein modification process	1
adenyl ribonucleotide binding	1
purine ribonucleoside triphosphate binding	1
protein binding	1
identical protein binding	1
protein dimerization activity	1
cell adhesion molecule binding	1
nucleoside phosphate binding	1
heterocyclic compound binding	1
kinase activity	1
phosphotransferase activity, alcohol group as acceptor	1
catalytic activity, acting on a protein	1
binding	1
transferase activity, transferring phosphorus-containing groups	1
catalytic activity	1
extracellular vesicle	1

Protein interactions and networks

STRING

740 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SLK	BET1L	Q9NYM9	395
SLK	ERBB2	P04626	383
SLK	ESRP1	Q6NXG1	359
SLK	SLC37A2	Q8TED4	353
SLK	ARHGEF1	Q92888	353
SLK	RALGPS2	Q86X27	353
SLK	FNIP1	Q8TF40	353
SLK	CIMAP1A	Q96PU9	348
SLK	EZR	P15311	327
SLK	SCYL2	Q6P3W7	323
SLK	DBF4B	Q8NFT6	321
SLK	CORO1B	Q9BR76	320
SLK	EXOC4	Q96A65	318
SLK	RDX	P35241	317
SLK	FAM117B	Q6P1L5	317

IntAct

89 interactions, top by confidence:

A	B	Type	Score
MED4	MED19	psi-mi:“MI:2364”(proximity)	0.900
MED17	MED19	psi-mi:“MI:0914”(association)	0.840
MOB1B	LATS1	psi-mi:“MI:0914”(association)	0.840
CFTR	ESYT2	psi-mi:“MI:2364”(proximity)	0.710
RHOD	PLXNB2	psi-mi:“MI:0914”(association)	0.640
SLK	SLK	psi-mi:“MI:0407”(direct interaction)	0.620
SNRNP27	UBA6	psi-mi:“MI:0914”(association)	0.530
BAG2	HGS	psi-mi:“MI:0914”(association)	0.530
ATP6V0A1	ATP6AP2	psi-mi:“MI:0914”(association)	0.530
	AP3D1	psi-mi:“MI:0914”(association)	0.460
	MYL12B	psi-mi:“MI:0914”(association)	0.460
TNFAIP3	LRRIQ3	psi-mi:“MI:2364”(proximity)	0.420
SLK	HSPA9	psi-mi:“MI:0915”(physical association)	0.400
SLK	AIFM1	psi-mi:“MI:0915”(physical association)	0.400
CLSTN1	SLK	psi-mi:“MI:0915”(physical association)	0.370
	ABL1	psi-mi:“MI:0914”(association)	0.350
	SGK1	psi-mi:“MI:0914”(association)	0.350
	TBKBP1	psi-mi:“MI:0914”(association)	0.350
	AURKA	psi-mi:“MI:0914”(association)	0.350
LRRK2		psi-mi:“MI:0914”(association)	0.350
KEAP1	VWA8	psi-mi:“MI:0914”(association)	0.350
ZDHHC5	IGKV2D-24	psi-mi:“MI:0914”(association)	0.350
	SHTN1	psi-mi:“MI:0914”(association)	0.350
IMMP2L	ANKHD1-EIF4EBP3	psi-mi:“MI:0914”(association)	0.350
RIPK2	CNOT1	psi-mi:“MI:0914”(association)	0.350

BioGRID (222): SLK (Affinity Capture-MS), ARHGEF1 (Co-fractionation), NSFL1C (Co-fractionation), PPP1R2 (Co-fractionation), RBM8A (Co-fractionation), SFN (Co-fractionation), SLK (Co-fractionation), SLK (Co-fractionation), YWHAB (Co-fractionation), YWHAZ (Co-fractionation), SLK (Affinity Capture-MS), SLK (Proximity Label-MS), SLK (Proximity Label-MS), SLK (Affinity Capture-MS), SLK (Affinity Capture-MS)

ESM2 similar proteins: A0A0A6YYL3, A1ZAC4, A6QP06, A8C984, B3NLX1, D2HXI8, E1BFR5, E1C2I2, E2RJI4, F4JQ51, F4JXF1, F4KBP5, H3BUK9, O08815, O54988, O55092, P15792, P20689, P51954, P51957, Q3UVR3, Q4R7T5, Q5RD27, Q5ZMS4, Q60DG4, Q61IS6, Q696W0, Q6NTJ3, Q6YY75, Q7TSC3, Q80XP9, Q8BI55, Q8C0P0, Q8N157, Q8N573, Q8NI08, Q8VCR8, Q94CU5, Q96GX5, Q96PY6

Diamond homologs: A4K2M3, A4K2P5, A4K2Q5, A4K2S1, A4K2T0, A4K2W5, A4K2Y1, A8XJW8, B0LT89, B7ZR30, E1BK52, E9PTG8, F1LP90, F1NBT0, H2L099, O00506, O08815, O14047, O14305, O24527, O54748, O54988, O55092, O55098, O61122, O61125, O75914, O88643, O94804, O95819, P35465, P70218, P83510, P97820, Q08E52, Q0IHQ8, Q12851, Q13043, Q13153, Q13177

SIGNOR signaling

5 interactions.

A	Effect	B	Mechanism
SLK	up-regulates	MAP3K5	phosphorylation
CSNK2A1	down-regulates	SLK	phosphorylation
SLK	“up-regulates activity”	TP53	phosphorylation
SLK	“up-regulates activity”	ETV5	phosphorylation

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 110 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
SARS-CoV Infections	8	6.1×	8e-03
Viral Infection Pathways	12	5.1×	9e-04
Infectious disease	14	4.8×	5e-04

Disease & clinical

Clinical variants and AI predictions

ClinVar

157 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	1
Uncertain significance	128
Likely benign	8
Benign	1

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
3064848	NM_014720.4(SLK):c.1414G>T (p.Glu472Ter)	Likely pathogenic

SpliceAI

2956 predictions. Top by Δscore:

Variant	Effect	Δscore
10:103967884:A:T	donor_gain	1.0000
10:103967894:AGG:A	donor_loss	1.0000
10:103967897:T:G	donor_loss	1.0000
10:103990667:A:AG	acceptor_gain	1.0000
10:103990668:T:G	acceptor_gain	1.0000
10:103990673:A:AG	acceptor_gain	1.0000
10:103990673:AG:A	acceptor_gain	1.0000
10:103990673:AGGCC:A	acceptor_gain	1.0000
10:103990674:G:A	acceptor_gain	1.0000
10:103990674:G:GA	acceptor_gain	1.0000
10:103990674:GGC:G	acceptor_gain	1.0000
10:103990674:GGCC:G	acceptor_gain	1.0000
10:103990674:GGCCC:G	acceptor_gain	1.0000
10:103990835:TTTGG:T	donor_gain	1.0000
10:103990836:TTGG:T	donor_gain	1.0000
10:103990837:TGG:T	donor_gain	1.0000
10:103990838:GG:G	donor_gain	1.0000
10:103990838:GGG:G	donor_gain	1.0000
10:103990839:GG:G	donor_gain	1.0000
10:103990840:G:GG	donor_gain	1.0000
10:103992981:T:G	acceptor_gain	1.0000
10:103992981:TAGA:T	acceptor_loss	1.0000
10:103992982:A:AG	acceptor_gain	1.0000
10:103992983:G:GA	acceptor_gain	1.0000
10:103992983:GA:G	acceptor_gain	1.0000
10:103992983:GAA:G	acceptor_gain	1.0000
10:103992983:GAAC:G	acceptor_gain	1.0000
10:103993129:ATTGG:A	donor_gain	1.0000
10:103993130:TTGG:T	donor_gain	1.0000
10:103993131:TGG:T	donor_gain	1.0000

AlphaMissense

8293 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
10:103967816:T:A	V24E	1.000
10:103967833:C:T	P30S	1.000
10:103967834:C:A	P30H	1.000
10:103967845:T:A	W34R	1.000
10:103967845:T:C	W34R	1.000
10:103967846:G:C	W34S	1.000
10:103967847:G:C	W34C	1.000
10:103967847:G:T	W34C	1.000
10:103967864:T:A	L40Q	1.000
10:103967864:T:C	L40P	1.000
10:103967866:G:A	G41S	1.000
10:103967866:G:C	G41R	1.000
10:103967866:G:T	G41C	1.000
10:103967867:G:A	G41D	1.000
10:103967867:G:T	G41V	1.000
10:103967872:G:A	G43R	1.000
10:103967872:G:C	G43R	1.000
10:103967873:G:A	G43E	1.000
10:103967873:G:T	G43V	1.000
10:103967876:C:A	A44D	1.000
10:103967878:T:A	F45I	1.000
10:103967878:T:C	F45L	1.000
10:103967878:T:G	F45V	1.000
10:103967879:T:C	F45S	1.000
10:103967879:T:G	F45C	1.000
10:103967880:T:A	F45L	1.000
10:103967880:T:G	F45L	1.000
10:103967881:G:A	G46R	1.000
10:103967881:G:C	G46R	1.000
10:103967881:G:T	G46W	1.000

dbSNP variants (sampled 300 via entrez): RS1000023067 (10:103969056 C>G,T), RS1000028672 (10:104015490 C>T), RS1000036997 (10:104015860 G>A), RS1000061387 (10:103992082 G>A), RS1000125455 (10:103985394 A>T), RS1000193985 (10:104009057 A>G), RS1000212352 (10:103972579 G>A), RS1000215996 (10:103967060 G>C), RS1000291593 (10:104006116 A>G), RS1000311593 (10:104013003 A>G), RS1000320614 (10:104005785 G>A,C), RS1000379249 (10:104021931 G>A,T), RS1000463235 (10:103969303 C>T), RS1000491136 (10:103985751 G>A), RS1000668402 (10:104026887 C>T)

Disease associations

OMIM: gene MIM:616563 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

10 associations (top):

Study	Trait	p-value
GCST001027_1	Uterine fibroids	9.000000e-14
GCST004744_57	Lung adenocarcinoma	6.000000e-11
GCST004748_17	Lung cancer	7.000000e-06
GCST005978_2	Diastolic blood pressure	2.000000e-08
GCST005993_49	Mean corpuscular hemoglobin	4.000000e-11
GCST006011_81	Mean corpuscular volume	5.000000e-12
GCST007703_92	Systolic blood pressure	2.000000e-06
GCST007705_21	Pulse pressure	2.000000e-08
GCST009158_37	Uterine fibroids	1.000000e-16
GCST010152_13	Neuroblastoma or malignant cutaneous melanoma	6.000000e-10

EFO canonical traits (4, from GWAS)

EFO ID	Trait name
EFO:0006336	diastolic blood pressure
EFO:0004527	mean corpuscular hemoglobin
EFO:0006335	systolic blood pressure
EFO:0005763	pulse pressure measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (2): CHEMBL4202 (SINGLE PROTEIN), CHEMBL4888459 (PROTEIN FAMILY)

Molecules with ChEMBL bioactivity

81 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 509,453 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL1173655	AFATINIB	4	15,144
CHEMBL1287853	FEDRATINIB	4	3,554
CHEMBL1289601	LENVATINIB	4	8,784
CHEMBL1289926	AXITINIB	4	15,732
CHEMBL1336	SORAFENIB	4	86,060
CHEMBL180022	NERATINIB	4	9,404
CHEMBL1983268	ENTRECTINIB	4	3,510
CHEMBL24828	VANDETANIB	4	42,230
CHEMBL288441	BOSUTINIB	4	12,255
CHEMBL3301607	FILGOTINIB	4	2,905
CHEMBL3301622	GILTERITINIB	4	2,395
CHEMBL477772	PAZOPANIB	4	15,540
CHEMBL502835	NINTEDANIB	4	8,545
CHEMBL535	SUNITINIB	4	79,020
CHEMBL5416410	DASATINIB	4	655
CHEMBL553	ERLOTINIB	4	108,300
CHEMBL554	LAPATINIB	4	69,326
CHEMBL576982	QUIZARTINIB	4	4,432
CHEMBL601719	CRIZOTINIB	4	14,403
CHEMBL608533	MIDOSTAURIN	4	7,259
CHEMBL939	GEFITINIB	4
CHEMBL2087361	ICOTINIB	3
CHEMBL217092	SARACATINIB	3
CHEMBL223360	LINIFANIB	3
CHEMBL270995	BRIVANIB ALANINATE	3
CHEMBL300138	ENZASTAURIN	3
CHEMBL3137331	DEFACTINIB	3
CHEMBL31965	CANERTINIB	3
CHEMBL3544983	TESEVATINIB	3
CHEMBL377300	BRIVANIB	3

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: enzyme — SLK subfamily

Most potent curated ligand interactions (2 total), top 2:

Ligand	Action	Affinity	Parameter
RN486	Inhibition	7.37	pKd
danusertib	Inhibition	6.21	pIC50

Binding affinities (BindingDB)

22 measured of 22 human assays (22 total across all organisms); most potent 22 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value	Patent
1-[2-(4-methylphenyl)-5-tert-butyl-pyrazol-3-yl]-3-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]urea	KD	0.37 nM
Staurosporine	KD	1.7 nM
4-(4-Fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)-1H-imidazole	KD	9.8 nM
4-[4-(4-fluorophenyl)-2-(4-methanesulfinylphenyl)-1H-imidazol-5-yl]pyridine	KD	12 nM
BMS-354825	KD	27 nM
N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazolin-4-amine	KD	150 nM
PKC-412	KD	190 nM
AMG 706	KD	300 nM
4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide	KD	370 nM
1-[4-(3-amino-1H-indazol-4-yl)phenyl]-3-(2-fluoro-5-methyl-phenyl)urea	KD	450 nM
(3Z)-4-amino-5-fluoro-3-[5-(4-methylpiperazino)-1,3-dihydrobenzimidazol-2-ylidene]carbostyril	KD	520 nM
(18S)-18-[(dimethylamino)methyl]-17-oxa-4,14,21-triazahexacyclo[19.6.1.1^{7,14}.0^{2,6}.0^{8,13}.0^{22,27}]nonacosa-1(28),2(6),7(29),8(13),9,11,22(27),23,25-nonaene-3,5-dione	KD	700 nM
N-[4-({4-[(3-methyl-1H-pyrazol-5-yl)amino]-6-(4-methylpiperazin-1-yl)pyrimidin-2-yl}sulfanyl)phenyl]cyclopropanecarboxamide	KD	1100 nM
ERLOTINIB HYDROCHLORIDE	KD	1200 nM
1-[4-[(4-ethyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl]-3-[4-[[6-(methylamino)-4-pyrimidinyl]oxy]phenyl]urea	KD	1400 nM
CI-1033	KD	1700 nM
GEFITINIB	IC50	2300 nM	US-9416123: Kinase modulators for the treatment of cancer
5-[(Z)-(5-fluoranyl-2-oxidanylidene-1H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[(2S)-3-morpholin-4-yl-2-oxidanyl-propyl]-1H-pyrrole-3-carboxamide	KD	2600 nM
1-Acyl-1H-[1,2,4]triazole-3,5-diamine Analogue 3b	KD	3100 nM
(E)-N-[4-(3-chloro-4-fluoro-anilino)-3-cyano-7-ethoxy-6-quinolyl]-4-(dimethylamino)but-2-enamide	KD	3500 nM
N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide	KD	3500 nM
1-methyl-5-[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]pyridin-4-yl]oxy-N-[4-(trifluoromethyl)phenyl]benzimidazol-2-amine	KD	4500 nM

ChEMBL bioactivities

549 potent at pChembl≥5 of 561 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
10.70	Kd	0.02	nM	STAUROSPORINE
10.62	Kd	0.024	nM	STAUROSPORINE
8.52	Kd	3	nM	FORETINIB
8.43	Ki	3.7	nM	CHEMBL4875188
8.41	Ki	3.9	nM	CHEMBL4878325
8.33	Kd	4.7	nM	BOSUTINIB
8.30	Kd	5	nM	CHEMBL4465866
8.30	Ki	5.012	nM	CHEMBL1974328
8.30	Ki	5.012	nM	TAE-684
8.22	Kd	6	nM	CHEMBL4576489
8.22	Ki	6	nM	CHEMBL4877889
8.21	IC50	6.14	nM	CHEMBL3326006
8.20	Ki	6.31	nM	CHEMBL1971029
8.18	Ki	6.6	nM	CHEMBL156277
8.11	IC50	7.8	nM	CHEMBL156277
8.10	Ki	7.943	nM	CHEMBL1970142
8.10	Ki	7.943	nM	CHEMBL1968406
8.10	Ki	7.943	nM	ILORASERTIB
8.09	IC50	8.2	nM	CHEMBL4875188
8.07	Ki	8.5	nM	CHEMBL157089
8.04	IC50	9.04	nM	STAUROSPORINE
8.01	Ki	9.7	nM	CHEMBL4856751
8.00	Ki	10	nM	CHEMBL1969588
8.00	Ki	10	nM	OSI-632
7.90	Ki	12.59	nM	CHEMBL1996817
7.90	Ki	12.59	nM	GW843682X
7.89	Ki	13	nM	CHEMBL4855513
7.89	Kd	13	nM	KW-2449
7.84	IC50	14.6	nM	STAUROSPORINE
7.82	Ki	15	nM	CHEMBL4869745
7.80	Ki	15.85	nM	CHEMBL1987034
7.80	Ki	15.85	nM	CEDIRANIB
7.80	Ki	15.85	nM	CHEMBL2006778
7.80	Ki	15.85	nM	CHEMBL1241473
7.80	Ki	15.85	nM	CHEMBL1982466
7.80	Ki	15.85	nM	CHEMBL2005631
7.79	IC50	16.1	nM	STAUROSPORINE
7.77	Ki	17	nM	CHEMBL4857159
7.77	Ki	17	nM	CHEMBL157141
7.77	Ki	17	nM	CHEMBL4868821
7.77	Ki	17	nM	CHEMBL4867952
7.75	Kd	18	nM	CRIZOTINIB
7.72	IC50	19	nM	STAUROSPORINE
7.71	Kd	19.48	nM	CHEMBL3752910
7.70	Ki	19.95	nM	CHEMBL1998585
7.70	Ki	19.95	nM	CHEMBL1967116
7.70	Ki	19.95	nM	CHEMBL1983111
7.70	Ki	19.95	nM	CHEMBL1965507
7.68	Ki	21	nM	CHEMBL349540
7.68	Kd	21	nM	TAE-684

PubChem BioAssay actives

240 with measured affinity, of 1563 total; 50 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
(2S,3R,4R,6R)-3-methoxy-2-methyl-4-(methylamino)-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8,10,12,14,19,21,23,25,27-nonaen-16-one	256578: Average Binding Constant for SLK; NA=Not Active at 10 uM	kd	<0.0001	uM
1-N’-[3-fluoro-4-[6-methoxy-7-(3-morpholin-4-ylpropoxy)quinolin-4-yl]oxyphenyl]-1-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide	625086: Binding constant for SLK kinase domain	kd	0.0030	uM
3-[[4-(2-methoxyphenyl)-2,5-dioxopyrrol-3-yl]amino]benzonitrile	1779839: Binding affinity human SLK by binding displacement assay	ki	0.0037	uM
3-[[4-(4-bromo-2-methoxyphenyl)-2,5-dioxopyrrol-3-yl]amino]benzonitrile	1779839: Binding affinity human SLK by binding displacement assay	ki	0.0039	uM
Bosutinib	625086: Binding constant for SLK kinase domain	kd	0.0047	uM
3-(2,2-difluoro-10,12-dimethyl-1-aza-3-azonia-2-boranuidatricyclo[7.3.0.03,7]dodeca-3,5,7,9,11-pentaen-4-yl)-N-[2-[2-[2-[2-[[(2S,3R,4R,6R)-3-methoxy-2-methyl-16-oxo-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8,10,12,14,19,21,23,25,27-nonaen-4-yl]amino]ethoxy]ethoxy]ethoxy]ethyl]propanamide	1526210: Binding affinity to recombinant N-terminal His-FLAG-GST-tagged SLK (unknown origin) (1 to 1152 residues) expressed in baculovirus infected Sf9 insect cells incubated for 1 hr by TR-FRET assay	kd	0.0050	uM
3-(2,2-difluoro-10,12-dimethyl-1-aza-3-azonia-2-boranuidatricyclo[7.3.0.03,7]dodeca-3,5,7,9,11-pentaen-4-yl)-N-[2-[2-[2-[2-[[(2S,3R,4R,6R)-3-methoxy-2-methyl-16-oxo-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8,10,12,14,19,21,23,25,27-nonaen-4-yl]-methylamino]ethoxy]ethoxy]ethoxy]ethyl]propanamide	1526210: Binding affinity to recombinant N-terminal His-FLAG-GST-tagged SLK (unknown origin) (1 to 1152 residues) expressed in baculovirus infected Sf9 insect cells incubated for 1 hr by TR-FRET assay	kd	0.0060	uM
3-(2-methoxyphenyl)-4-(naphthalen-1-ylamino)pyrrole-2,5-dione	1779839: Binding affinity human SLK by binding displacement assay	ki	0.0060	uM
4-[2-(butylamino)-5-[4-[(4-methylpiperazin-1-yl)methyl]phenyl]pyrrolo[2,3-d]pyrimidin-7-yl]cyclohexan-1-ol	1185906: Inhibition of SLK (unknown origin) by Off-chip Mobility Shift Assay	ic50	0.0061	uM
3-(3-chloroanilino)-4-(2-methoxyphenyl)pyrrole-2,5-dione	1779839: Binding affinity human SLK by binding displacement assay	ki	0.0066	uM
3-(3-chloro-4-hydroxyanilino)-4-(2-methoxyphenyl)pyrrole-2,5-dione	1779839: Binding affinity human SLK by binding displacement assay	ki	0.0085	uM
3-[[4-(5-bromo-2-methoxyphenyl)-2,5-dioxopyrrol-3-yl]amino]benzonitrile	1779839: Binding affinity human SLK by binding displacement assay	ki	0.0097	uM
[4-[(E)-2-(1H-indazol-3-yl)ethenyl]phenyl]-piperazin-1-ylmethanone	625086: Binding constant for SLK kinase domain	kd	0.0130	uM
3-(3-fluoroanilino)-4-(2-methoxyphenyl)pyrrole-2,5-dione	1779839: Binding affinity human SLK by binding displacement assay	ki	0.0130	uM
3-(1,3-benzodioxol-5-ylamino)-4-(2-methoxyphenyl)pyrrole-2,5-dione	1779839: Binding affinity human SLK by binding displacement assay	ki	0.0150	uM
3-(2-methoxyphenyl)-4-(3-methylsulfanylanilino)pyrrole-2,5-dione	1779839: Binding affinity human SLK by binding displacement assay	ki	0.0170	uM
3-(2-methoxyphenyl)-4-(quinolin-6-ylamino)pyrrole-2,5-dione	1779839: Binding affinity human SLK by binding displacement assay	ki	0.0170	uM
N-[4-[4-(3-cyanoanilino)-2,5-dioxopyrrol-3-yl]-3-methoxyphenyl]-2-methylpropanamide	1779839: Binding affinity human SLK by binding displacement assay	ki	0.0170	uM
3-(3-chloro-4-hydroxyanilino)-4-(2-chlorophenyl)pyrrole-2,5-dione	1779839: Binding affinity human SLK by binding displacement assay	ki	0.0170	uM
Crizotinib	625086: Binding constant for SLK kinase domain	kd	0.0180	uM
4-methyl-3-[(1-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2149436: Binding affinity to human SLK incubated for 45 mins by Kinobead based pull down assay	kd	0.0195	uM
5-chloro-2-N-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]-4-N-(2-propan-2-ylsulfonylphenyl)pyrimidine-2,4-diamine	625086: Binding constant for SLK kinase domain	kd	0.0210	uM
3-(2-methoxyphenyl)-4-(4-methylsulfanylanilino)pyrrole-2,5-dione	1779839: Binding affinity human SLK by binding displacement assay	ki	0.0210	uM
3-(4-methoxyanilino)-4-(2-methoxyphenyl)pyrrole-2,5-dione	1779839: Binding affinity human SLK by binding displacement assay	ki	0.0220	uM
4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazoline	625086: Binding constant for SLK kinase domain	kd	0.0220	uM
1-[4-[(4-ethylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-3-[4-[6-(methylamino)pyrimidin-4-yl]oxyphenyl]urea	435832: Binding constant for SLK kinase domain	kd	0.0230	uM
3-(2-methoxyphenyl)-4-(4-phenylanilino)pyrrole-2,5-dione	1779839: Binding affinity human SLK by binding displacement assay	ki	0.0250	uM
Erlotinib	435832: Binding constant for SLK kinase domain	kd	0.0260	uM
3-(3-chloroanilino)-4-(2-chlorophenyl)pyrrole-2,5-dione	1779839: Binding affinity human SLK by binding displacement assay	ki	0.0280	uM
3-(3-methoxyanilino)-4-(2-methoxyphenyl)pyrrole-2,5-dione	1779839: Binding affinity human SLK by binding displacement assay	ki	0.0290	uM
3-[(4-naphthalen-1-yl-2,5-dioxopyrrol-3-yl)amino]benzonitrile	1779839: Binding affinity human SLK by binding displacement assay	ki	0.0290	uM
3-[[4-[4-(2,6-dichloro-3-pyridinyl)-2-methoxyphenyl]-2,5-dioxopyrrol-3-yl]amino]benzonitrile	1779839: Binding affinity human SLK by binding displacement assay	ki	0.0300	uM
6-[[5-fluoro-2-(3,4,5-trimethoxyanilino)pyrimidin-4-yl]amino]-2,2-dimethyl-4H-pyrido[3,2-b][1,4]oxazin-3-one	625086: Binding constant for SLK kinase domain	kd	0.0330	uM
3-(2-chlorophenyl)-4-(3-methylsulfanylanilino)pyrrole-2,5-dione	1779839: Binding affinity human SLK by binding displacement assay	ki	0.0330	uM
(15S,16S,18R)-16-hydroxy-16-(hydroxymethyl)-15-methyl-28-oxa-4,14,19-triazaoctacyclo[12.11.2.115,18.02,6.07,27.08,13.019,26.020,25]octacosa-1,6,8,10,12,20,22,24,26-nonaen-3-one	508087: Binding affinity to SLK	kd	0.0350	uM
3-(4-hydroxyanilino)-4-(2-methoxyphenyl)pyrrole-2,5-dione	1779839: Binding affinity human SLK by binding displacement assay	ki	0.0350	uM
3-(4-benzoylanilino)-4-(2-methoxyphenyl)pyrrole-2,5-dione	1779839: Binding affinity human SLK by binding displacement assay	ki	0.0370	uM
3-[[4-(2-methoxy-5-phenylphenyl)-2,5-dioxopyrrol-3-yl]amino]benzonitrile	1779839: Binding affinity human SLK by binding displacement assay	ki	0.0400	uM
3-(2-chlorophenyl)-4-(4-hydroxyanilino)pyrrole-2,5-dione	1779839: Binding affinity human SLK by binding displacement assay	ki	0.0400	uM
3-[[4-(2-chlorophenyl)-2,5-dioxopyrrol-3-yl]amino]benzonitrile	1779839: Binding affinity human SLK by binding displacement assay	ki	0.0410	uM
3-(2-methoxyphenyl)-4-(4-thiophen-3-ylanilino)pyrrole-2,5-dione	1779839: Binding affinity human SLK by binding displacement assay	ki	0.0430	uM
6-cyclopropyl-8-fluoro-2-[2-(hydroxymethyl)-3-[1-methyl-5-[[5-(4-methylpiperazin-1-yl)-2-pyridinyl]amino]-6-oxo-3-pyridinyl]phenyl]isoquinolin-1-one	1357752: Inhibition of SLK (unknown origin)	ic50	0.0430	uM
3-(2-chlorophenyl)-4-(3-fluoroanilino)pyrrole-2,5-dione	1779839: Binding affinity human SLK by binding displacement assay	ki	0.0440	uM
4-[5-[4-[(4-methyl-1,4-diazepan-1-yl)methyl]phenyl]-2-[[(2S)-pentan-2-yl]amino]pyrrolo[2,3-d]pyrimidin-7-yl]cyclohexan-1-ol	1409259: Inhibition of N-terminal GST-tagged full length human SLK (1 to 1152 end residues) expressed in baculovirus expression system using fluorecence-labeled substrate by MCE assay	ic50	0.0470	uM
3-(2-methoxyphenyl)-4-(4-morpholin-4-ylanilino)pyrrole-2,5-dione	1779839: Binding affinity human SLK by binding displacement assay	ki	0.0470	uM
4-[[5-amino-1-(2,6-difluorobenzoyl)-1,2,4-triazol-3-yl]amino]benzenesulfonamide	435832: Binding constant for SLK kinase domain	kd	0.0480	uM
methyl 2-hydroxy-3-[N-[4-[methyl-[2-(4-methylpiperazin-1-yl)acetyl]amino]phenyl]-C-phenylcarbonimidoyl]-1H-indole-6-carboxylate	625086: Binding constant for SLK kinase domain	kd	0.0510	uM
Sunitinib	435832: Binding constant for SLK kinase domain	kd	0.0560	uM
3-(2-chlorophenyl)-4-(3-hydroxyanilino)pyrrole-2,5-dione	1779839: Binding affinity human SLK by binding displacement assay	ki	0.0560	uM
N-[5-[[5-chloro-4-(2-propan-2-ylsulfonylanilino)pyrimidin-2-yl]amino]-2-[2-(dimethylamino)ethyl-methylamino]-4-methoxyphenyl]prop-2-enamide	1584375: Inhibition of recombinant full length GST-tagged human SLK expressed in baculovirus expression system by LanthaScreen assay	ic50	0.0580	uM

CTD chemical–gene interactions

47 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Tobacco Smoke Pollution	affects expression, increases expression	2
Valproic Acid	increases expression	2
aristolochic acid I	decreases expression	1
FR900359	affects phosphorylation	1
dicrotophos	decreases expression	1
propionaldehyde	increases methylation	1
nonanal	increases methylation	1
sodium arsenate	decreases expression	1
n-hexanal	increases methylation	1
arsenite	affects binding, decreases reaction	1
tris(1,3-dichloro-2-propyl)phosphate	increases expression	1
butyraldehyde	increases methylation	1
coumarin	affects phosphorylation	1
caprylic aldehyde	increases methylation	1
pentanal	increases methylation	1
heptanal	increases methylation	1
CPG-oligonucleotide	increases expression	1
Grape Seed Proanthocyanidins	increases expression, affects cotreatment	1
jinfukang	decreases expression	1
Resveratrol	affects cotreatment, increases expression	1
Air Pollutants	increases abundance, decreases expression	1
Benzo(a)pyrene	increases expression	1
Caffeine	affects phosphorylation	1
Catechin	increases expression, affects cotreatment	1
Clorgyline	increases expression	1
Enzyme Inhibitors	decreases activity, increases O-linked glycosylation	1
Estradiol	increases expression	1
Formaldehyde	decreases expression	1
Furaldehyde	affects cotreatment, decreases expression	1
Ivermectin	decreases expression	1

ChEMBL screening assays

280 unique, capped per target: 279 binding, 1 functional

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1004491	Binding	Binding affinity to human recombinant SLK expressed in Escherichia coli assessed as thermal shift by differential scanning fluorimetry	Discovery of a potent and selective inhibitor for human carbonyl reductase 1 from propionate scanning applied to the macrolide zearalenone. — Bioorg Med Chem
CHEMBL1963827	Functional	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: SLK	PubChem BioAssay data set

Cellosaurus cell lines

5 cell lines: 5 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_D1QL	Abcam K-562 SLK KO	Cancer cell line	Female
CVCL_D2M7	Abcam Raji SLK KO	Cancer cell line	Male
CVCL_TP42	HAP1 SLK (-) 1	Cancer cell line	Male
CVCL_TP43	HAP1 SLK (-) 2	Cancer cell line	Male
CVCL_WQ56	Abcam Jurkat SLK KO	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.